Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Consolidated Financial Results and Performance
BSX logo

Boston Scientific Achieves 11.6% Sales Growth Amid Strategic Acquisitions and Global Expansion

BSX10-QFiling Date: 5/1/2026
Boston Scientific Corporation
Description

What this story covers

Boston Scientific reported strong Q1 2026 results with $5.2 billion in sales, driven by Cardiovascular growth and the Nalu acquisition. Despite ongoing patent and securities litigation, the company maintains robust liquidity and a strategic focus on operational efficiency.

Story snapshot

CompanyBoston Scientific Corporation
TickerBSX
VariantStandard detailed
Duration11:48
Filing type10-Q
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000885725-26-000033
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in